Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
46
MLTX Quote, Financials, Valuation and Earnings
Last price:
$14.89
Seasonality move
:
19.6%
Day range:
$14.84 - $15.34
52-week range:
$5.95 - $62.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.65x
Volume:
1.3M
Avg. volume:
2.2M
1-year change:
-72.15%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$3.33
Analysts' Opinion
-
Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 6 Hold ratings, and 2 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $14.61, MoonLake Immunotherapeutics has an estimated downside of -1.97% from its current price of $14.90.
-
Price Target UpsideAccording to analysts, the highest upside price target is $30.00 representing -100% upside increase from its current price of $14.90.
Fair Value
-
According to the consensus of 16 analysts, MoonLake Immunotherapeutics has -1.97% downside to fair value with a price target of $14.61 per share.
MLTX vs. S&P 500
-
Over the past 5 trading days, MoonLake Immunotherapeutics has overperformed the S&P 500 by 8.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MoonLake Immunotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MoonLake Immunotherapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MoonLake Immunotherapeutics reported revenues of --.
Earnings Growth
-
MoonLake Immunotherapeutics earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter MoonLake Immunotherapeutics reported earnings per share of -$1.10.
Enterprise value:
753.2M
EV / Invested capital:
2.05x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-4.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.2M
Return On Assets:
-44.86%
Net Income Margin (TTM):
--
Return On Equity:
-53.14%
Return On Invested Capital:
-47.62%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$13.2K | -$86.7K | -$3.2M | -$32.5K | -$745K | |
| Operating Income | -$55.8M | -$108.5M | -$229.2M | -$43.1M | -$71.4M | |
| EBITDA | -$55.8M | -$108.5M | -$226M | -$43.1M | -$70.7M | |
| Diluted EPS | -$0.94 | -$1.29 | -$3.33 | -$0.56 | -$1.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2M | $88.5M | $500M | $512.3M | $411.2M | |
| Total Assets | $116.2M | $88.6M | $500.2M | $518.2M | $414.3M | |
| Current Liabilities | $2.1M | $6M | $10.3M | $20.1M | $48.4M | |
| Total Liabilities | $6.1M | $6M | $10.6M | $22.7M | $123.1M | |
| Total Equity | $110.2M | $82.6M | $489.6M | $495.5M | $291.2M | |
| Total Debt | -- | -- | $13.1K | $1.9M | $74.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42M | -$80.5M | -$185.7M | -$25.3M | -$44.5M | |
| Cash From Investing | -$132.1M | $58.6M | $85.6M | $58.3M | $88.4M | |
| Cash From Financing | $451.3M | $79.6M | $73.8M | $183.1K | $480K | |
| Free Cash Flow | -$42M | -$81.1M | -$185.9M | -$25.4M | -$44.5M | |
MLTX
Sector
Market Cap
$1.1B
$28.5M
Price % of 52-Week High
23.75%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-3.33%
-1.33%
1-Year Price Total Return
-72.15%
-20.32%
Beta (5-Year)
1.211
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.77
200-day SMA
Sell
Level
$37.26
Bollinger Bands (100)
Sell
Level
11.15 - 55.17
Chaikin Money Flow
Buy
Level
8.5M
20-day SMA
Buy
Level
$13.01
Relative Strength Index (RSI14)
Buy
Level
57.32
ADX Line
Buy
Level
17.84
Williams %R
Sell
Level
-15.0794
50-day SMA
Buy
Level
$11.84
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
55.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (82.9612)
Buy
CA Score
(Annual)
Level (0.2621)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.0664)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Stock Forecast FAQ
In the current month, MLTX has received 8 Buy ratings 6 Hold ratings, and 2 Sell ratings. The MLTX average analyst price target in the past 3 months is $14.61.
-
Where Will MoonLake Immunotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that MoonLake Immunotherapeutics share price will drop to $14.61 per share over the next 12 months.
-
What Do Analysts Say About MoonLake Immunotherapeutics?
Analysts are divided on their view about MoonLake Immunotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MoonLake Immunotherapeutics is a Sell and believe this share price will rise from its current level to $2.00.
-
What Is MoonLake Immunotherapeutics's Price Target?
The price target for MoonLake Immunotherapeutics over the next 1-year time period is forecast to be $14.61 according to 16 Wall Street analysts, 8 of them rate the stock a Buy, 2 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is MLTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MoonLake Immunotherapeutics is a Buy. 8 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MLTX?
You can purchase shares of MoonLake Immunotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MoonLake Immunotherapeutics shares.
-
What Is The MoonLake Immunotherapeutics Share Price Today?
MoonLake Immunotherapeutics was last trading at $14.89 per share. This represents the most recent stock quote for MoonLake Immunotherapeutics. Yesterday, MoonLake Immunotherapeutics closed at $14.90 per share.
-
How To Buy MoonLake Immunotherapeutics Stock Online?
In order to purchase MoonLake Immunotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MLTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MLTX
Sector
P/E ratio
--
23.75x
PEG ratio
-0.03x
-0.01x
P/B ratio
3.65x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MLTX
Sector
Revenue growth
--
4.85%
Earnings growth
-95.56%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.92
-$0.20
Profitability
MLTX
Sector
Profitability FY 2024
-$1.4M
$3.6M
Return on invested capital
-47.62%
-30.98%
Return on assets
-44.86%
-27.62%
Return on equity
-53.14%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
MLTX
Sector
Total cash
$380.5M
$27.2M
Short term investments
$267.6M
$25.7M
Total assets
$477.9M
$79.7M
Long term debt
$74.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
